FTRE Quote, Financials, Valuation and Earnings

Humana, Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of 0.59%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Humana, Inc.'s return on equity of 7.3%.

Fortrea Holdings, Inc. has a consensus price target of $13.25, signalling downside risk potential of -25.12%. On the other hand Humana, Inc. has an analysts' consensus of $287.83 which suggests that it could grow by 11.03%. Given that Humana, Inc. has higher upside potential than Fortrea Holdings, Inc., analysts believe Humana, Inc. is more attractive than Fortrea Holdings, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.462, suggesting its less volatile than the S&P 500 by 53.84%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana, Inc. offers a yield of 1.37% to investors and pays a quarterly dividend of $0.89 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Humana, Inc. pays out 35.45% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are smaller than Humana, Inc. quarterly revenues of $32.6B. Fortrea Holdings, Inc.'s net income of -$15.9M is lower than Humana, Inc.'s net income of $194M. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Humana, Inc.'s PE ratio is 24.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.58x versus 0.25x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Medpace Holdings, Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of 16.84%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Medpace Holdings, Inc.'s return on equity of 78.26%.

Fortrea Holdings, Inc. has a consensus price target of $13.25, signalling downside risk potential of -25.12%. On the other hand Medpace Holdings, Inc. has an analysts' consensus of $541.92 which suggests that it could fall by -5.24%. Given that Fortrea Holdings, Inc. has more downside risk than Medpace Holdings, Inc., analysts believe Medpace Holdings, Inc. is more attractive than Fortrea Holdings, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Medpace Holdings, Inc. has a beta of 1.427, suggesting its more volatile than the S&P 500 by 42.743%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medpace Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Medpace Holdings, Inc. pays out -- of its earnings as a dividend.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are larger than Medpace Holdings, Inc. quarterly revenues of $659.9M. Fortrea Holdings, Inc.'s net income of -$15.9M is lower than Medpace Holdings, Inc.'s net income of $111.1M. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Medpace Holdings, Inc.'s PE ratio is 39.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.58x versus 7.34x for Medpace Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare, Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of 0.69%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Molina Healthcare, Inc.'s return on equity of 19.74%.

Fortrea Holdings, Inc. has a consensus price target of $13.25, signalling downside risk potential of -25.12%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $176.63 which suggests that it could grow by 8.05%. Given that Molina Healthcare, Inc. has higher upside potential than Fortrea Holdings, Inc., analysts believe Molina Healthcare, Inc. is more attractive than Fortrea Holdings, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.516, suggesting its less volatile than the S&P 500 by 48.37%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are smaller than Molina Healthcare, Inc. quarterly revenues of $11.5B. Fortrea Holdings, Inc.'s net income of -$15.9M is lower than Molina Healthcare, Inc.'s net income of $79M. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Molina Healthcare, Inc.'s PE ratio is 10.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.58x versus 0.20x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of 33.68%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Merck & Co., Inc.'s return on equity of 39.63%.

Fortrea Holdings, Inc. has a consensus price target of $13.25, signalling downside risk potential of -25.12%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.37%. Given that Merck & Co., Inc. has higher upside potential than Fortrea Holdings, Inc., analysts believe Merck & Co., Inc. is more attractive than Fortrea Holdings, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.08% to investors and pays a quarterly dividend of $0.85 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Fortrea Holdings, Inc.'s net income of -$15.9M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.58x versus 4.20x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.